ACB
BEARISH
$3.43
Live
Aurora Cannabis Inc. · NASDAQ
Target $6.36
(+85.5%)
$3.28
52W Range
$6.67
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$194.51M
P/E
N/A
ROE
-15.5%
Profit margin
-22.5%
Debt/Equity
0.18
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Aurora Cannabis Inc. (ACB) exhibits severe financial distress signals, underscored by a Piotroski F-Score of 1/9—indicating extreme weakness in operational and financial health. The absence of an Altman Z-Score and persistent negative profitability metrics (ROE: -15.51%, ROA: -4.36%) suggest high bankruptcy risk, especially given the company's negative earnings and declining cash flow. Despite a low price-to-book (0.49) and price-to-sales (0.52), the stock trades at a significant discount due to deteriorating fundamentals and a 96.9% 5-year decline. The lack of analyst coverage and neutral insider activity further erode confidence in near-term recovery.
Key Strengths
Low price-to-book ratio (0.49) suggests potential undervaluation on a balance sheet basis
Strong gross margin (36.03%) indicates efficient production and cost control
High current ratio (3.06) reflects strong short-term liquidity
Debt-to-equity ratio of 0.18 is low, indicating conservative capital structure
Recent quarter showed a positive Q/Q EPS growth of +103.3%, signaling possible operational improvement
Key Risks
Piotroski F-Score of 1/9 indicates severe financial distress and poor operational performance
Negative ROE (-15.51%) and ROA (-4.36%) reflect persistent unprofitability
Earnings growth has collapsed by -94.70% YoY, with a -93.60% Q/Q decline
No analyst coverage and no dividend yield suggest lack of institutional confidence
Historical earnings surprises are highly erratic and consistently negative, with an average surprise of -641.57% over the last 4 quarters
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
22
Weak
45
30
20
15
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 1/9, Negative earnings and ROE, High volatility and 5-year price decline, No analyst coverage, Erratic earnings surprises
Confidence
85%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Price-to-book of 0.49 suggests deep discount to book value
- Price-to-sales of 0.52 is below industry average
Watchpoints
- No Graham Number or intrinsic value due to negative earnings
- Negative earnings and cash flow undermine valuation models
- High growth expectations not supported by current fundamentals
Future
30/100
Ref Growth rates
Positives
- Revenue growth of 6.80% YoY suggests some top-line stability
- Recent Q/Q EPS growth of +103.3% may indicate turnaround
Watchpoints
- Earnings growth is -94.70% YoY and -93.60% Q/Q
- Forward P/E of -31.18 implies continued losses
- No clear path to sustained profitability
Past
20/100
Ref Historical trends
Positives
- Some quarters have beaten estimates (e.g., +135.3% surprise in 2026-02-04)
- Historical revenue growth has been positive in prior periods
Watchpoints
- Average earnings surprise of -641.57% over last 4 quarters
- Persistent negative earnings and declining profitability
- 5-year price drop of 96.9% reflects long-term underperformance
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt-to-equity (0.18) and high current ratio (3.06) indicate strong liquidity
- No Altman Z-Score available, but low leverage is a positive
Watchpoints
- Piotroski F-Score of 1/9 is extremely low, signaling financial distress
- Negative ROE and ROA indicate poor capital efficiency
- No operating cash flow or free cash flow data available
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- No history of dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.43
Analyst Target
$6.36
Upside/Downside
+85.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACB and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACB
Aurora Cannabis Inc.
Primary
|
-96.9% | -52.9% | -20.2% | -29.6% | -0.3% | -2.3% |
|
ADAG
Adagene Inc.
Peer
|
-81.2% | +188.8% | +109.6% | +84.4% | +33.2% | +45.4% |
|
KRMD
KORU Medical Systems, Inc.
Peer
|
+27.2% | +4.2% | +84.7% | -1.9% | -6.7% | -2.5% |
|
ARCT
Arcturus Therapeutics Holdings Inc.
Peer
|
-87.2% | -57.7% | -51.9% | -61.4% | -9.7% | -6.0% |
|
ANIK
Anika Therapeutics, Inc.
Peer
|
-62.2% | -47.2% | -6.6% | +63.8% | +38.5% | +0.6% |
ACB
Aurora Cannabis Inc.
Primary
5Y
-96.9%
3Y
-52.9%
1Y
-20.2%
6M
-29.6%
1M
-0.3%
1W
-2.3%
ADA
Adagene Inc.
Peer
5Y
-81.2%
3Y
+188.8%
1Y
+109.6%
6M
+84.4%
1M
+33.2%
1W
+45.4%
KRM
KORU Medical Systems, Inc.
Peer
5Y
+27.2%
3Y
+4.2%
1Y
+84.7%
6M
-1.9%
1M
-6.7%
1W
-2.5%
ARC
Arcturus Therapeutics Holdings Inc.
Peer
5Y
-87.2%
3Y
-57.7%
1Y
-51.9%
6M
-61.4%
1M
-9.7%
1W
-6.0%
ANI
Anika Therapeutics, Inc.
Peer
5Y
-62.2%
3Y
-47.2%
1Y
-6.6%
6M
+63.8%
1M
+38.5%
1W
+0.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-31.18
PEG Ratio
N/A
P/B Ratio
0.49
P/S Ratio
0.52
EV/Revenue
0.59
EV/EBITDA
-6.68
Market Cap
$194.51M
Profitability
Profit margins and return metrics
Profit Margin
-22.51%
Operating Margin
2.32%
Gross Margin
36.03%
ROE
-15.51%
ROA
-4.36%
Growth
Revenue and earnings growth rates
Revenue Growth
+6.8%
Earnings Growth
-94.7%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-93.6%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.18
Low debt
Current Ratio
3.06
Strong
Quick Ratio
1.05
Good
Cash/Share
$1.91
Quarterly Earnings History
EPS performance vs analyst estimates
2026-06-17
$N/A
2026-02-04
$0.03
+135.3% surprise
2025-11-05
$-0.91
-810.0% surprise
2025-08-06
$-0.27
-1250.0% surprise
Healthcare Sector Comparison
Comparing ACB against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
Return on Equity (ROE)
-15.51%
This Stock
vs
-49.88%
Sector Avg
-68.9%
(Below Avg)
Profit Margin
-22.51%
This Stock
vs
-9.43%
Sector Avg
+138.6%
(Superior)
Debt to Equity
0.18
This Stock
vs
3.74
Sector Avg
-95.2%
(Less Debt)
Revenue Growth
6.8%
This Stock
vs
80.78%
Sector Avg
-91.6%
(Slower)
Current Ratio
3.06
This Stock
vs
3.72
Sector Avg
-17.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACB
Aurora Cannabis Inc.
|
BEARISH | $194.51M | - | -15.5% | -22.5% | $3.43 | |
|
ADAG
Adagene Inc.
|
BULLISH | $194.65M | - | -63.3% | -% | $4.13 | Compare |
|
KRMD
KORU Medical Systems, Inc.
|
NEUTRAL | $195.82M | - | -15.6% | -6.4% | $4.21 | Compare |
|
ARCT
Arcturus Therapeutics Holdings Inc.
|
BEARISH | $189.87M | - | -28.9% | -80.2% | $6.68 | Compare |
|
ANIK
Anika Therapeutics, Inc.
|
BEARISH | $204.78M | - | -6.7% | -9.6% | $14.2 | Compare |
ACB
Aurora Cannabis Inc.
BEARISH
Mkt Cap
$195M
P/E
-
ROE
-15.5%
Price
$3.43
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-09-23 | Martin (Miguel) | Senior Officer of Issuer | Stock Award | 60,024 | - |
| 2025-09-23 | Schick (Lori) | Senior Officer of Issuer | Stock Award | 13,265 | - |
| 2025-09-23 | Schick (Lori) | Senior Officer of Issuer | Disposition in the public market at price 5.12 per | 7,352 | $37,627 |
| 2025-09-19 | Martin (Miguel) | Senior Officer of Issuer | Stock Award | 860 | - |
Martin (Miguel)
Senior Officer of Issuer
2025-09-23
60,024 shares
Schick (Lori)
Senior Officer of Issuer
2025-09-23
13,265 shares
Schick (Lori)
Senior Officer of Issuer
2025-09-23
7,352 shares
·
$37,627
Martin (Miguel)
Senior Officer of Issuer
2025-09-19
860 shares
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning ACB from our newsroom.
Newest → oldest
No matching news yet.